AnaptysBio Files 8-K Under 'Other Events'

TL;DR

ANAB filed an 8-K, check for 'Other Events' news.

AI Summary

AnaptysBio, Inc. filed an 8-K on November 21, 2025, reporting an event on November 20, 2025. The filing is under 'Other Events' and does not specify a particular transaction or development, suggesting it might be a routine update or a minor disclosure.

Why It Matters

This filing indicates a disclosure event for AnaptysBio, Inc. on November 20, 2025, requiring investors to check the details for any material information.

Risk Assessment

Risk Level: low — The filing is a standard 8-K under 'Other Events' without immediate indication of significant financial or operational changes.

Key Players & Entities

• ANAPTYSBIO, INC (company) — Registrant
• November 20, 2025 (date) — Date of earliest event reported
• November 21, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of Incorporation
• 20-3828755 (other) — Commission File Number
• 10770 Wateridge Circle, Suite 210, San Diego, CA 92121 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke

Filing Documents

• anab-20251120.htm (8-K) — 28KB
• 0001370053-25-000096.txt ( ) — 183KB
• anab-20251120.xsd (EX-101.SCH) — 2KB
• anab-20251120_def.xml (EX-101.DEF) — 9KB
• anab-20251120_lab.xml (EX-101.LAB) — 29KB
• anab-20251120_pre.xml (EX-101.PRE) — 20KB
• anab-20251120_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On November 20, 2025, AnaptysBio, Inc. ( AnaptysBio ) filed a Verified Complaint (the " Complaint ") in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. has materially breached the parties' Collaboration and Exclusive License Agreement (" Collaboration Agreement ") and that GlaxoSmithKline (" GSK " ) , Tesaro's corporate parent, has tortiously interfered with the Collaboration Agreement. AnaptysBio has requested that the court declare that AnaptysBio is entitled to all rights and remedies under the Collaboration Agreement. The Complaint contends that Tesaro breached, and GSK induced Tesaro to breach, multiple material Collaboration Agreement terms. Under these terms, Tesaro agreed that it would not conduct or participate in research, development, manufacturing or commercialization of any PD-1 antagonist other than those licensed by AnaptysBio to Tesaro. The Collaboration Agreement also provides that Tesaro will "use Commercially Reasonable Efforts to . . . obtain the optimum commercial return for [Jemperli] in all major markets throughout the world." Despite these obligations, the Complaint contends that Tesaro (i) violated its exclusivity obligations by participating in past, ongoing, and upcoming governed clinical trials with PD-1 antagonists that compete with Jemperli, including Keytruda, and (ii) failed to use Commercially Reasonable Efforts to obtain the "optimum commercial return" for Jemperli by, among other things, participating in a course of conduct with GSK to favor GSK's antibody-drug conjugate (ADC) product candidates, including by pairing those ADCs with PD-1 antagonists that directly compete with Jemperli . In 2020, AnaptysBio similarly filed a complaint against GSK regarding breaches of its obligations under the Collaboration Agreement. Those breaches at the time related to GSK's planned clinical trial of Zejula, another of GSK's oncology programs, in combination with Keytruda, without the consent

Forward-Looking Statements

Forward-Looking Statements This filing contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential termination of the Collaboration Agreement, the timing and potential outcome of proceedings in Delaware Chancery Court, the return of Jemperli to the company, and the nature of the remedies we may obtain in such proceedings. Statements including words such as "plan," "seek," "will," "expect," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this filing, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AnaptysBio, Inc. Date: November 21, 2025 By: /s/Eric Loumeau Name: Eric Loumeau Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR